(All fields required)
Please enter a valid email.
Please enter your name.
Russell E. Ware, MD, PhD Director, Division of Hematology
is a recognized expert in sickle cell disease. He is the national PI for several NHLBI-funded sickle cell clinical trials, and has recently begun an international program to improve the diagnosis, treatment, and research for sickle cell disease in developing countries. His laboratory focuses on genetic modifiers of sickle cell disease, as well as the pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea therapy.
Director, Division of Hematology
Marjory J. Johnson Chair of Hematology Translational Research, Division of Hematology
Co-Executive Director, Cancer and Blood Diseases Institute
Associate Director, Global Health Center
Professor, UC Department of Pediatrics
Sickle cell disease; hemolytic anemia; immune-mediated cytopenia; PNH
MD: Duke University School of Medicine, Durham, NC, 1979-83.
Residency: Baylor College of Medicine, Houston, TX, 1983-86.
Fellowship: Duke Medical Center, Durham, NC, 1986-89.
PhD: Duke University School of Medicine, Durham, NC, 1987-91.
Certification: Pediatric Hematology/Oncology.
Ware RE, Hall SG, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med. 1991;325:991.
Kinney TR, Helms RW, O’Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood. 1999;94:1550-1554.
Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle cell anemia. J Pediatr. 2001;139:790-796.
Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematological efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103:2039-2045.
Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145:346-352.
Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers Transcranial doppler flow velocities in children with sickle cell anemia. Blood. 2007;110:1043-1047.
Wang WC, Ware RE, Miller ST, Iyer RV, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomized, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer M, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985-4991.
Ware RE and Helms RW for the SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119(17):3925-3932.
Ware RE. Is sickle cell anemia a neglected tropical disease? PLoS Negl Trop Dis. 2013.
Ralph A. Gruppo, MD Director, Comprehensive Hemophilia and Thrombosis Center
research involves numerous clinical trials of promising therapies for hemophilia, von Willebrand Disease, and hemolytic uremic syndrome. His research also includes the study of thrombosis in children, including the use of site-directed thrombolytic therapy in the prevention of long-term complications of thrombosis.
Director, Comprehensive Hemophilia and Thrombosis Center
Director, Research Coagulation Laboratory
Director, Special Hemostasis & Thrombosis Laboratory
Coagulation; hemophilia; thrombosis
Gruppo RA. Treatment of hemophilia in developing countries: a journey of a thousand miles. Pediatr Blood Cancer. 2010 Mar;54(3):348-9. No abstract available
Gelfand MJ, Gruppo RA, Nasser MP. Ventilation-perfusion scintigraphy in children and adolescents is associated with a low rate of indeterminate studies. Clin Nucl Med. 2008 Sep;33(9):606-9.
Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord. 2007 Sep 15;22(12):1813-5.
Balasa VV, Gruppo RA, Glueck CJ, Wang P, Roy DR, Wall EJ, Mehlman CT, Crawford AH. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am. 2004 Dec;86-A(12):2642-7.
Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII -- a robust meta-analytic finding. Haemophilia. 2004 Sep;10(5):449-51.
Morrison JA, Gruppo R, Glueck CJ, Stroop D, Fontaine RN, Wang P, Smith KL. Population-specific alleles: the polymorphism (K121Q) of the human glycoprotein PC-1 gene is strongly associated with race but not with insulin resistance in black and white children. Metabolism. 2004 Apr;53(4):465-8.
Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis -- a meta-analysis. Haemophilia. 2003 May;9(3):251-60. Review.
Balasa VV, Kalinyak KA, Bean JA, Stroop D, Gruppo RA. Hyperhomocysteinemia is associated with low plasma pyridoxine levels in children with sickle cell disease. J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):374-9.
McNamara JL, Lombardi JP, Ferguson R, Manning PB, Gruppo RA. Alternative methods for anticoagulation monitoring in pediatric patients with applicability to a patient with severe hemophilia A and circulating inhibitor. J Extra Corpor Technol. 2001 Dec;33(4):239-42.
Gruppo R, Degrauw A, Fogelson H, Glauser T, Balasa V, Gartside P. Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. J Pediatr. 2000 Nov;137(5):714-8.
Theodosia A. Kalfa, MD, PhD
Associate Professor, UC Department of Pediatrics
Signaling in erythrocytes; erythropoiesis; sickle cell disease; reactive oxygen species
Visit the Kalfa Lab.
George A, Pushkaran S, Konstantinidis DG, Koochaki S, Malik P, Mohandas N, Zheng Y, Joiner CH, Kalfa TA. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood. Epub ahead of print. 2013.
Konstantinidis DG, Pushkaran S, Johnson JF, Cancelas JA, Manganaris S, Harris CE, Williams DA, Zheng Y, Kalfa TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012 Jun 21;119(25):6118-27.
Hammill AM, Risinger MA, Joiner CH, Keddache M, Kalfa TA. Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. Br J Haematol. 2011 Jan 31.
Kalfa TA. Anchoring at an island to relieve stress. Blood. 2011 Jan 20;117(3):748-9.
Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2010 Oct 14.
Konstantinidis DG, George A, Kalfa TA. Rac GTPases in erythroid biology. Transfus Clin Biol. 2010 Sep;17(3):126-30.
Kalfa TA, Pushkaran S, Zhang X, Johnson JF, Pan D, Daria D, Geiger H, Cancelas JA, Williams DA, Zheng Y. Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. Haematologica. 2010 Jan;95(1):27-35.
Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood. 2010 Feb 4;115(5):936-47.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Daria D, Filippi MD, Knudsen ES, Faccio R, Li Z, Kalfa T, Geiger H. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood. 2008 Feb 15;111(4):1894-902.
Rho GTPases in Terminal Erythroid Maturation. Principal Investigator. NIH/NHLBI. Sep 2012-Jun 2016. #1R01HL116352.
Erythrocyte Cytoskeleton Disorders Diagnostic Core. Principal Investigator. CCTST PCS T1 Pilot. July 2013- June 2015.
Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-investigator. NIH/NHLBI. Aug 2013–May 2018. # U01 HL117709.
TCD with Transfusions Changing to Hydroxyurea. Co-investigator. NIH/Baylor. Aug 2009-Jul 2014. #R01HL095647.
Karen A. Kalinyak, MD Outpatient Clinical Director
Outpatient Clinical Director
Hematology; bone marrow failure; sickle cell anemia; hemoglobinopathy
Crosby LE, Barach I, McGrady ME, Kalinyak KA, Eastin AR, Mitchell MJ. Integrating interactive web-based technology to assess adherence and clinical outcomes in pediatric sickle cell disease. Anemia. 2012;2012:492428.
Debaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele G, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Gordon MO, Miller JP, Ichord RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure. Blood. 2012 Apr;119(16):3684-90.
McCarville MB, Rogers ZR, Sarnaik S, Scott P, Aygun B, Hilliard L, Lee MT, Kalinyak K, Owen W, Garro J, Schultz W, Yovetich N, Ware RE, SWiTCH Investigators. Effects of Chronic Transfusions on Abdominal Sonographic Abnormalities in Children with Sickle Cell Anemia. J Pediatr. 2012 Feb;160(2):281-285.
Kwiatkowski JL, Yim E, Miller S, Adams RJ, STOP 2 Study Investigators. Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr Blood Cancer. 2011 May;56(5):777-82.
George A, Benton J, Pratt J, Kim MO, Kalinyak KA, Kalfa TA, Joiner CH. The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Pediatr Blood Cancer. 2011 Feb.
Wang W, Brugnara C, Snyder C, Wynn L, Rogers Z, Kalinyak K, Brown C, Qureshi A, Bigelow C, Neumayr L, Smith-Whitley K, Chui DH, Delahunty M, Woolson R, Steinberg M, Telen M, Kesler K. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. Br J Haematol. 2011 Jan;1365-2141.
Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2011 May;56(5):840-2.
Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W, Comprehensive Sickle Cell Centers Clinical Trial Consortium. Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Center Clinical Trial Consortium (CTC). Pediatr Blood Cancer. 2010 Sep;55(3):485-94.
Jordan LC, McKinstry RC 3rd, Kraut MA, Ball WS, Vendt BA, Casella JF, DeBaun MR, Strouse JJ, Silent Infarct Transfusion Trial Investigators. Incidental findings on brain magnetic resonance imaging of children with sickle cell disease. Pediatrics. 2010 Jul;126(1):53-61.
Vichinsky EP, Neumayr LD, Gold JI, Weiner MW, Rule RR, Truran D, Kasten J, Eggleston B, Kesler K, McMahon L, Orringer EP, Harrington T, Kalinyak K, DeCastro LM, Kutlar A, Rutherford C, Johnson C, Bessman JD, Jordan LB, Armstrong FD. Neuropsychological Dysfunction and Neuroimaging Adult Sickle Cell Anemia Study Group. JAMA. 2010;303(18):1823-31.
Patrick T. McGann, MD, MS
focuses his research efforts on improving the diagnosis, care, and outcomes for children with sickle cell anemia across the world, particularly in sub-Saharan Africa. Current projects include the investigation of hydroxyurea in Africa (REACH), the development and testing of inexpensive point-of-care diagnostics in hematology, and analysis of serotype distribution of invasive pneumococcal disease in Angola.
Assistant Professor, UC Department of Pediatrics
Dr. McGann was a leader in the development of a newborn screening and treatment program in the Republic of Angola. Toward this end, he worked and lived in Angola for much of two and a half years. This work helped to develop many relationships and is the foundation for much of his continued research and public health efforts in Angola. His research efforts during this time were supplemented by formal training in clinical research through the American Society of Hematology's Clinical Research Training Institute and through the master's program in clinical research at Baylor College of Medicine.
He is also actively involved in global hematology and global child health through such organizations as the Global Sickle Cell Disease Network, the Central African Sickle Cell Network (REDAC), the American Society of Hematology, and the AAP's Section on International Child Health (SOICH).
Upon arrival to Cincinnati Children's, Dr. McGann was the recipient of the Procter Scholar Award, which will help to support his international research efforts.
MD: Tufts University School of Medicine, Boston, MA 2006.
Residency: Pediatrics, Massachusetts General Hospital, Boston, MA 2009.
Fellowship: Pediatric Hematology-Oncology, St. Jude Children's Research Hospital, 2009-2011; Baylor College of Medicine, 2011-2012.
MS: Clinical Research, Baylor College of Medicine, 2013.
Board Certification: Pediatrics, 2009; Pediatric Hematology-Oncology, 2013.
McGann PT, Bernardino L. Anemia falciforme: um grande problema de saúde pública em Angola. Jornal Angolano de Medicina. 2013; 1(3).
McGann PT, Ferris MG, Ramamurthy, U, Santos, B, de Oliveira V, Bernardino L, Ware RE. A pilot newborn screening and treatment for sickle cell anemia in the Republic of Angola. Am J Hematol. 2013; 88(12):984-989.
Despotovic JM, McGann PT, Smeltzer MP, Aygun B, Ware RE. RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia. Pediatr Blood Cancer. 2013; 60(9):E106-108.
McGann PT, Flanagan JM, Howard TA, Dertinger SD, He J, Kulharya A, Thompson BW, Ware RE. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial. Pediatr Blood Cancer. 2012; 59(2) 254-257.
McGann PT, Despotovic JM, Howard TA, Ware RE. A novel laboratory technique demonstrating the influences of RHD zygosity and the RhCcEe phenotype on erythrocyte D antigen expression. Am J Hematol. 2012; 87(3): 266-271.
McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Curr Opin Hematol. 2011 May;18(3):158-65.
McGann PT, Howard TA, Flanagan JM, Lahti JM, Ware RE. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011; 154(1):134-40.
McGann PT, McDade J, Mortier NA, Combs MR, Ware RE. IgA-mediated autoimmune hemolytic anemia in an infant. Pediatr Blood Cancer. 2011; 56(5):837-9.
McDade J, McGann PT. 50 Years Ago in The Journal of Pediatrics: Autohemolytic Anemia in Young Infants. J Pediatr. 2011; 159(1):69.
McGann PT, Ware RE. 50 years ago in the journal of pediatrics overwhelming infection in children following splenectomy. J Pediatr. 2010; 157(2):202.
Identification of serotype distribution causing invasive pneumococcal disease among Angolan children. Principal Investigator. Thrasher Research Fund-Early Career Award. Aug 2012-July 2014.
A Phase I/II Study of Hydroxyurea for Children with Sickle Cell Anemia in Angola. Principal Investigator. Procter Scholar Award, Cincinnanti Children's Hospital Medical Center TAPS Program. Jan 2014-Dec 2016.
Sickle Cell Education and Screening for Angolan Adolescents. Co-Director/Mentor. AAP International Community Access to Child Health (ICATCH), Jan 2014-Dec 2016.
Eric Mullins, MD
has a research interest in the interplay between the hemostatic system and the immune system in the setting of inflammatory diseases and infection.
Joseph S. Palumbo, MD
Interactions between the hemostatic system and innate immunity effecting tumor progression; Langerhans' cell histiocytosis
Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, Flick MJ, Queiroz KC, Shi K, Spek CA, Conway EM, Monia BP, Weiler H, Degen JL, Palumbo JS. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011 Jul 25.
Flick MJ, Chauhan AK, Frederick M, Talmage KE, Kombrinck KW, Miller W, Mullins ES, Palumbo JS, Zheng X, Esmon NL, Esmon CT, Thornton S, Becker A, Pelc LA, Di Cera E, Wagner DD, Degen JL. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood. 2011 Jun 9;117(23):6326-37.
Akunuru S, Palumbo J, Zhai QJ, Zheng Y. Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. PLoS One. 2011 Feb 9;6(2):e16951.
Palumbo JS, Degen JL. Mechanisms coupling the hemostatic system to colitis-associated cancer. Thromb Res. 2010 Apr;125 Suppl 2:S39-43. Review.
Steinbrecher KA, Horowitz NA, Blevins EA, Barney KA, Shaw MA, Harmel-Laws E, Finkelman FD, Flick MJ, Pinkerton MD, Talmage KE, Kombrinck KW, Witte DP, Palumbo JS. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res. 2010 Apr 1;70(7):2634-43.
Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost. 2008 Mar;34(2):154-60. Review.
Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, Kombrinck KW, Talmage KE, Souri M, Ichinose A, Degen JL. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost. 2008 May;6(5):812-9.
Palumbo JS, Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res. 2007;120 Suppl 2:S22-8.
Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007 Nov;117(11):3224-35.
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007 Jul 1;110(1):133-41.
Charles T. Quinn, MD, MS Director, Hematology Clinical and Translational Research
investigates causes and ways to predict, prevent and treat brain injury in sickle cell disease, such as stroke and cognitive dysfunction, both locally in Cincinnati and as a member of national and international study teams. Other areas of research include developing a method to directly measure of red blood cell turnover rate in sickle cell disease, identification and treatment of cardiomyopathy and nephropathy in sickle cell disease, and new agents to treat and prevent pain (VOC) in sickle cell disease.
Director, Hematology Clinical and Translational Research
Director, Hemoglobinopathy Laboratory
Sickle cell disease; thalassemia; hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; immune thrombocytopenia (ITP); neutropenia; stroke
Epidemiology, pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; identification and treatment of cardiomyopathy and nephropathy in sickle cell disease; treatment and prevention of pain (VOC) in sickle cell disease; MRI methods of iron quantitation; new agents for immune thrombocytopenia (ITP)
Dr. Quinn’s main interests and expertise are in patient-oriented and translational research in sickle cell disease and thalassemia. His formal clinical and translational research training has included: (1) the NIH-K30 Curriculum in Patient-Oriented Research; (2) the Clinical Research Training Institute of the American Society of Hematology; (3) the NIH-K12/KL2 Clinical Scholars Program; and (4) a master’s degree in clinical sciences. Dr. Quinn is a member of the Editorial Board for Pediatric Blood and Cancer and the Board of Contributing Editors for The Hematologist. Dr. Quinn is on the Medical Advisory Board for the Cooley’s Anemia Foundation, and he is a member of the Committee on Educational Affairs of the American Society of Hematology. Locally, he is the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.
MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.
MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.
Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.
Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.
Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.
McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. National trends in incidence rates of hospitalization for stroke in children with sickle sell disease. Pediatr Blood Cancer. Epub ahead of print. 2013.
Quinn CT, McKinstry RC, Dowling MM, Ball WS, Kraut MA, Casella JF, Dlamini N, Ichord RN, Jordan LC, Kirkham FJ, Noetzel MJ, Roach ES, Strouse JJ, Kwiatkowski JL, Hirtz D, DeBaun MR. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol (formerly Arch Neurol). 2013;70(1):58-65.
Dowling MM, Quinn CT, Plumb P, Rogers ZR, Rollins NK, Koral K, Buchanan GR. Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. Blood. 2012;120(19):3891-7.
Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld E, Haines D, Pakbaz Z, Thompson AA, Quinn CT, Grady R, Sobota A, Olivieri N, Horne R, Yamashita R; Thalassemia Clinical Research Network. Beliefs about chelation among thalassemia patients. Health Qual Life Outcomes. 2012;10:148(1-21).
Quinn CT, Dowling MM. Cerebral tissue hemoglobin saturation in children with sickle cell disease. Pediatr Blood Cancer. 2012;59(5):881-887.
Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichisnky EP. Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet. 2012;112(7):980-990.
DeBaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele GE, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Hirtz DG, Gordon MO, Miller JP, Ichord, RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure. Blood. 2012;119(16):3684-90.
Kwiatkowski JL, Kim H-Y, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichisnky EP, Boudreaux JM, Porter JB, Coates T, Olivieri NF, Neufeld EJ, Thalassemia Clinical Research Network. Chelation Use and Iron Burden in North American and British Thalassemia Patients: A report from the Thalassemia Longitudinal Cohort. Blood. 2012;119(12):2746-53.
McCavit TL, Lin H, Zhang S, Ahn C, Flores G, Quinn CT. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer. 2012;58(6):945-9.
Quinn CT, Stuart MJ, Kesler K, Ataga KI, Wang WC, Styles L, Smith-Whitley K, Wun T, Raj A, Hsu L, Krishnan S, Kuypers FA, Setty S, Rhee S, Key NS, Buchanan GR. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol. 2011;155(2):263-7.
Measuring RBC Turnover by Stable Isotope Labeling in SCD. Principle Investigator. CCTST T1 Pilot Grant (CTSA). Jun 2012 - May 2013.
Hydroxyurea to prevent CNS complications of sickle cell disease in children. Co-Investigator. National Institutes of Health (NHLBI). Sep 2011 - Jul 2013. # R34HL108756.
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia. Co-Investigator. National Institutes of Health (NHLBI). Apr 2012 - Mar 2017. #P50HL110790.
Cristina Tarango, MD
MD: Stanford University School of Medicine, Stanford, CA, 2003.
Residency: Yale-New Haven Hospital, New Haven, CT, 2006.
Fellowship: University of Texas Southwestern Medical Center Dallas, Dallas, TX, 2009.
Certification: Pediatrics, 2006. Pediatric Hematology Oncology, 2011.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2014 Cincinnati Children's Hospital Medical Center